Sinew Pharma Inc. (6634) announced on September 25 that it hosted a pre-conference workshop at the 8th MASH Drug Development Summit, where it presented the results of its phase II clinical trial for SNP-610. The workshop's theme was " Exploring Non-Invasive Tests & Biomarkers for MASH in Action " It also brought together global industry and academic experts to discuss innovative trends and challenges in the treatment of MASH.
The summit, held from September 24 to 26 in Boston, USA, gathered medical experts, industry leaders, and research institutions from around the world to discuss the latest research, clinical trials, and drug development in MASH.
Sinew Pharma Inc. highlighted that its clinical trial results focused on the safety and efficacy of its multi-target MASH candidate drug, the SNP-6 series. These data represent significant progress in the field of MASH treatment, offering promising therapeutic options for patients.
In addition to Sinew Pharma, major pharmaceutical companies such as Madrigal (the first to launch a MASH drug), Roche, AstraZeneca, Merck, Pfizer, and Bristol Myers Squibb were also present at the conference. This underscores Sinew Pharma Inc.'s prominent position in global MASH research, receiving attention and recognition on par with these international giants.
Sinew Pharma's Chairman Kai-Min Chu stated, "We are honored to present our latest clinical research results at this conference and to explore the future of MASH therapy through workshops and roundtable discussions with global leaders. This is not only an opportunity to advance our research but also an important platform for fostering global collaborations and licensing opportunities.”
